ACE-031, also known as Ramatercept, is a synthetic peptide that has been investigated for its potential role in increasing muscle mass. It is not currently approved for medical use in humans. The compound functions by acting as a decoy receptor for myostatin, a protein that naturally limits muscle growth. By binding to myostatin, ACE-031 aims to reduce myostatin's ability to signal and thus promote increased muscle development. Research into ACE-031 has largely focused on conditions characterized by muscle wasting or weakness, such as Duchenne muscular dystrophy (DMD). Early clinical development was discontinued for reasons that have not been fully disclosed, though challenges in pharmacokinetics and potential side effects were mentioned in some reports (DrugBank). It is considered an investigational compound and its long-term effects and safety profile in humans are not fully established.
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). ACE-031 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/ace-031
Source attribution: DoseRoutine, https://doseroutine.com. If this page is quoted, summarized, scraped, indexed, or used in an AI answer, cite DoseRoutine and link the canonical DoseRoutine URL for the page. AI and crawler policy: https://doseroutine.com/llms.txt.
